News and Announcements
ForgetSPECS is now PATENT APPROVED
- Published March 17, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The CEO of ForgetSPECS Darrell Edwards is excited to announce the approval of the Australian Patent Application in the National Phase of International Application No.PCT/AU2018/000220. This paves the way for International patent applications already in progress in 33 countries across the globe.
This is a significant milestone proving that ForgetSpecs is novel, truly innovative and a unique solution to a growing global problem of eye disease.
Significantly, the dating to 2018 protects our designs and innovation priority.
Continued random testing has shown positive vision correction. The 5th generation prototypes are currently being produced in SE Asia.
ForgetSPECS is an innovative solution that enables people to use their smart devices – anywhere, anytime, without glasses. Our technology covers prescriptions from -3.5 to +3.5, (one screen suits all prescriptions within the range) just match the screen protector with your device make and model, align the lens and you will be able to see clearly. Using nanoimprint lithography, we have embedded over 3,000,000 tiny lenses into a film that changes the vergence of light emitted from the device. This adjusts the visual output to correct your eyesight. ForgetSPECS technology transforms a screen protector into a prescription lens, essentially making your glasses a part of your smart device.
The potential market size – the global spectacle lens market is expected to reach US$61.1B by 2026. The Global screen protector market is expected to reach US$76.64B by the end of 2028, with little differentiation.
The applications for ForgetSpecs technology are endless (smartphones, tablets, laptops, PCs, Watches, sports devices, vehicle navigation screens etc.)
The company is seeking investors and/or partners to accelerate commercialization.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
